Transatlantic Business Dialogue
Five CEOs from U.S. generic pharmaceutical companies are invited to participate in TABD's CEO conference in Berlin Oct. 29-30. The group, which convenes working groups to allow U.S. and EU business leaders to develop recommendations on trade policy, issued invitations Sept. 7 to Ivax CEO Philip Frost, MD, Schein CEO Martin Sperber, Sicor CEO Carlo Salvi, Barr CEO Bruce Downey, and Mylan CEO Milan Puskar to attend the conference. The generic industry had been excluded from previous discussions on generic pharmaceutical trade issues, resulting in FDA's withdrawal from involvement in TABD meetings
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth